ANTICORPOS ANTI-PD-L1 CANINO, USO TERAPÊUTICO DO MESMOS, POLINUCLEOTÍDEOS, VETORES, CÉLULA E COMPOSIÇÃO FARMACÊUTICA QUE COMPREENDE OS ANTICORPOS
Fully canine antibodies derived from a species-specific phage display library address the challenges of immunogenic liabilities in chimeric antibodies, offering high-affinity treatments for canine cancers by inhibiting PD-L1, enhancing treatment efficacy and safety for canine malignancies.
BR112025020416A2Pending Publication Date: 2026-11-10ADIVO GMBH
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- BR112025020416
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-27
- Filing Date
- 2024-03-26
- Publication Date
- 2026-11-10
Abstract
The present invention relates to anti-canine PD-L1 antibodies. The antibodies are preferably fully-canine antibodies. The present invention further relates to epitopes of canine PD-L1 that are bound by these antibodies and which inhibit binding of canine PD-1 to PD-L1. The invention further relates to use of the antibodies of the present invention in the treatment of dogs, including cancer treatment.
Need to check novelty before this filing date? Find Prior Art
